CureDuchenne Link Webinar: Power the Science
How You Can Help Researchers Find Treatments UPDATE: This event has been postponed due to a last-minute issue and will need to be rescheduled. Don’t miss this informative webinar on […]
How You Can Help Researchers Find Treatments UPDATE: This event has been postponed due to a last-minute issue and will need to be rescheduled. Don’t miss this informative webinar on […]
It is well understood that resting Ankle Foot Orthoses are recommended as standard of care for those with Duchenne muscular dystrophy. In many cases, that is the only lower extremity […]
**UPDATE** Duchenne gene therapy developers and scientific experts discuss AAV in DMD: Antitransgene SAEs. Please watch this webinar to learn more about recent concerns in gene therapy clinical trials. **ORIGINAL POST** […]
In this webinar, the NS Pharma team presents updates for the Duchenne community: Access programs for Viltepso, which is suitable for individuals with Duchenne who are amenable to exon 53 […]
Our presenters take us through the ins and out of mobile arm supports that are currently available, how they work, who they work for and other details. Many individuals living […]
This webinar, in partnership with the University of Kansas Medical Center, explores topics like achieving milestones, quality of life, and setting goals in families navigating Duchenne muscular dystrophy. The panelists […]
Children and adults with complex neuromuscular disorders such as Duchenne muscular dystrophy depend on others for controlling their environment, their mobility and most daily living activities. There are new technologies […]
Currently, there is a clear paucity of information to guide exercise prescription for patients with DMD. While clinical concerns based on the notion that excessive exercise may exacerbate the disease […]
Join us for a presentation on the clinical development process behind approved therapies and the importance of dose and administration of corticosteroids by Dr. Emma Ciafaloni. This presentation will be […]